Highlights Include Pledge to End Diabetes Stigma, Nasdaq Closing Bell Ceremony, and Educational Events
ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a series of initiatives in recognition of National Diabetes Awareness Month and World Diabetes Day.
“Our commitment to people with diabetes extends beyond our innovative insulin delivery technology,” said Jim Hollingshead, President and Chief Executive Officer. “World Diabetes Day may be just one day on the calendar, but for those living with diabetes, every day requires resilience and strength. By raising awareness today, we pave the way for a world where care, support, and understanding are accessible to all who need it.”
World Diabetes Day
World Diabetes Day is recognized globally on Tuesday, November 14, and the Insulet team will appear at the Nasdaq Stock Market for the ninth consecutive year by ringing the closing bell at 4:00 p.m. ET. Mr. Hollingshead will be joined by a group of global Insulet employees and customers and will speak about the importance of raising diabetes awareness and Insulet’s mission. The Nasdaq Stock Market closing bell ceremony will be aired live on the Nasdaq website and broadcast on CNBC and MSNBC TV.
Earlier that day, Insulet employees will join the American Association of Nurse Practitioners (AANP) at NBC’s TODAY Show, to recognize Nurse Practitioner Week and the important role nurse practitioners play in diabetes management. The intersection of World Diabetes Day and Nurse Practitioner Week provides the perfect opportunity to highlight Insulet employees who are also professionally trained and certified as nurse practitioners.
Diabetes Awareness Month Activities
Pledge to End Diabetes Stigma – Insulet has endorsed an international campaign to eliminate diabetes stigma and discrimination. The diaTribe Foundation and the Australian Centre for Behavioural Research in Diabetes are convening the global diabetes community to encourage non-profits, industry partners, healthcare professionals, people with diabetes, and allies and the general public to endorse the pledge.
Education for Clinicians – Members of the Association of Diabetes Care and Education Specialists (ADCES) based in New England are invited to Insulet’s Acton, Massachusetts global headquarters on November 2. The event, hosted by the ADCES Massachusetts Coordinating Body, is designed to empower and support clinicians in their care of people with diabetes.
#JustMyType Social Media Campaign – Insulet is encouraging the global diabetes community to create awareness and increase representation of people with diabetes through its #JustMyType campaign. The Company will feature content on its social media channels and will encourage others to participate on their own social channels.
Omnipod Ambassador Event – On November 11, Insulet is co-hosting a special event for Podders® and Dexcom Warriors from Germany and the UK, bringing content creators together to collaborate and create diabetes-related content to educate the public, broaden awareness, and inspire people with diabetes.
Orli Adamski is a 16-year-old from New York who has been advocating for people with diabetes since she was diagnosed at age seven. Ms. Adamski will join the Insulet team at the Nasdaq closing bell ceremony, representing the Podder community, just as she did last summer as a delegate to JDRF’s 2023 Children’s Congress.
“There are no breaks with type 1 diabetes,” said Ms. Adamski. “It impacts every single moment of my life, and so many other lives. It’s important to create awareness of the challenges that people with diabetes face, including gaining access to technology like Omnipod 5.”
In order to better serve Insulet’s customers, the Company is also planning various employee events and activities to increase awareness of diabetes.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections and zero fingersticks. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
©2023 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Deborah R. Gordon
Vice President, Investor Relations
Angela Geryak Wiczek
Senior Director, Corporate Communications